Table 2. Clinicopathological characteristics associated with low LRP1 immunohistochemical expression in adenocarcinomatous cells.
| n | Mean LRP1 tumor score | p univariate | p multivariate | |
|---|---|---|---|---|
| Sex | 307 | 0.0006 ‡ | n.s | |
| Male | 174 | 5.64 ± 4.01 | ||
| Female | 133 | 4.03 ± 4.03 | ||
| Age | 307 | 0.0009 ‡ | 0.09 | |
| ≤ 71 years | 140 | 5.78 ± 4.2 | ||
| > 71 years | 167 | 4.24 ± 3.89 | ||
| Tumor location | 307 | <0.0001 ‡ | 0.0004 | |
| Right | 136 | 3.34 ± 3.60 | ||
| Left | 171 | 6.22 ± 4.02 | ||
| UICC stage | 304 | 0.20 † | NA | |
| Stage I | 35 | 6.2 ± 3.53 | ||
| Stage II | 115 | 5.07 ± 4.37 | ||
| Stage III | 79 | 4.76 ± 4.12 | ||
| Stage IV | 75 | 4.45 ± 3.79 | ||
| Vascular invasion | 300 | 0.30 ‡ | NA | |
| Yes | 129 | 4.71 ± 4.1 | ||
| No | 171 | 5.2 ± 4.07 | ||
| Perineural invasion | 300 | 0.51 ‡ | NA | |
| Yes | 87 | 4.75 ± 3.97 | ||
| No | 213 | 5.09 ± 4.14 | ||
| Budding score | 286 | 0.49 ‡ | NA | |
| High | 14 | 4.21 ± 4.28 | ||
| Low | 272 | 4.99 ± 4.08 | ||
| Differentiation grade | 307 | <0.0001 ‡ | n.s | |
| Grade 1-2 | 258 | 5.44 ± 4.03 | ||
| Grade 3 | 49 | 2.35 ± 3.39 | ||
| CDX2 | 303 | 0.0003 ‡ | n.s | |
| Positive | 278 | 5.19 ± 3.98 | ||
| Negative | 25 | 2.16 ± 4.19 | ||
| Mucinous type | 287 | 0.004 ‡ | n.s | |
| Yes | 19 | 2.37 ± 3.58 | ||
| No | 268 | 5.14 ± 4.06 | ||
| Annexin A10 | 305 | <0.0001 ‡ | n.s | |
| Positive | 39 | 1.90 ± 3.31 | ||
| Negative | 266 | 5.41 ± 4.01 | ||
| KRAS status | 149 | 0.003 ‡ | n.s | |
| Wild type | 101 | 3.35 ± 3.72 | ||
| Mutant | 48 | 5.31 ± 3.82 | ||
| BRAF status | 303 | <0.0001 ‡ | 0.009 | |
| Wild type | 259 | 5.5 ± 3.93 | ||
| Mutant | 44 | 1.29 ± 2.69 | ||
| Microsatellite status | 305 | <0.0001 ‡ | 0.01 | |
| MSS | 265 | 5.52 ± 3.96 | ||
| MSI | 40 | 1.1 ± 2.47 | ||
| CIMP status | 62 | 0.02 † | NA | |
| No CIMP | 23 | 5.09 ± 3.94 | ||
| CIMP-Low | 32 | 3.75 ± 4.54 | ||
| CIMP-High | 7 | 0 ± 0 |
NA : Not adopted ; n.s : not significant; ‡ T test † Linear regression.